Biotech, Medtech & Diagnostics Branding Agency
Why a trial result does not establish a company
Trials, endpoints, approvals, reimbursement. Every claim you make is read by someone who can check it and by a regulator who can act on it. The brand has to be persuasive under a constraint most categories never face: it has to be literally true.
What a biotech, medtech & diagnostics branding agency does
A biotech, medtech & diagnostics branding agency positions and explains biotechnology, life sciences, medtech, medical device, diagnostics and synthetic biology companies so technical and financial buyers can judge the purchase rather than the demonstration. Everything Deep Tech builds category and positioning, naming, narrative, identity, messaging and brand book.
| Best for | Biotechnology, life sciences, medtech, medical device, diagnostics and synthetic biology companies. |
|---|---|
| What goes wrong | A trial result proves a compound. It does not prove a company. |
| What you get | Category and positioning, naming, narrative, identity, messaging, brand book. Where you sit against standard of care, the platform companies and the option of doing nothing. |
| Timeline | 9–16 weeks from kickoff to a finished brand system. Fixed scope, fixed timeline, one price. |
| Readers held in one brand | the clinician, the regulator and the investor. |
| Category | Therapeutic, platform, device or diagnostic. The label decides your comparables, your regulatory path and your multiple. |
A trial result proves a compound. It does not prove a company.
Five reasons a studio that does good work for software brands produces something thin for a biotech, medtech and diagnostics company.
- →Claims are regulated. Copy that would be ordinary elsewhere is a compliance problem here. Most studios discover this at legal review, after the design is done.
- →The evidence is the argument. Endpoints, power, cohort. Differentiation lives in figures most agencies cut because they look dry, and clinicians read nothing else.
- →Stage gets blurred. Preclinical language borrowed from approved products reads as dishonest to the exact audience you need. Precision about stage is a trust asset.
- →Three readers, three tests. The clinician tests the endpoint. The regulator tests the claim. The investor tests the market. One page, three failure modes.
- →Timelines outlast brands. Ten years and several pivots between founding and approval. An identity built around the lead programme rarely survives it.
Positioning first, identity second.
Category and positioning
Where you sit against standard of care, the platform companies and the option of doing nothing.
Naming
Company, platform and programme. A system that survives a product name arriving at approval.
Narrative
Mechanism, evidence and outcome, written so a clinician nods and an investor follows.
Identity
A system that survives a scientific poster, a booth, a regulatory submission and a recruiting post.
Messaging
Per audience: clinicians, regulators, payers and investors, with claim boundaries written down.
Brand book
Rules tight enough to hold when your team applies them without us.
The translation is the product everyone else is missing.
Weeks from kickoff to a finished brand system. Fixed scope, fixed timeline, one price.
Engineers across strategy, 3D, delivery and the build. The person writing your evidence story can read the paper.
Readers held in one brand: the clinician, the regulator and the investor.
Positioning decides what the brand claims. The website is where a specialist decides whether to believe it.
Biotech, medtech and diagnostics branding questions, from founders.
Can you work within regulated claim language?
Yes, and the boundaries go into the brand book so they hold after we leave. In this category the constraint is the craft, not an obstacle to it.
Do you have life sciences experience?
Adjacent rather than deep: Cloudphysician on the clinical side, and a decade of work in categories where evidence and regulation decide the sale. We will be straight about where that stops.
What does it cost?
Fixed scope and fixed timeline, quoted after the 30-minute call. Never a day rate and never an open-ended retainer.
How long does it take?
Nine to sixteen weeks for positioning, narrative, identity and brand book. Fixed scope, fixed timeline, one price.
Do you sign NDAs before seeing the technology?
Yes, and it is the normal starting point. Most of what makes a deep tech company defensible is unpublished.
Adjacent rather than deep, and provable: Cloudphysician, on critical care software and a tele-ICU copilot.
Send us the data package and your regulatory path.
Thirty minutes, no deck. We will tell you which category you are being read into, which part of your advantage is invisible on the page, and what we would change first.
Book a 30-minute audit →